Boardroom Alpha
Boardroom Alpha
SERA · Current Report (Form 8-K) · Filed June 4, 2026

Sera Prognostics Inc — Current Report (Form 8-K)

Form
8-K
Filed
June 4, 2026
Period
Jun 4, 2026
Ticker
SERA
Accession
0001534969-26-000032
Boardroom Alpha · Filing insights

Stockholders elected two Class II directors to 3-year terms and ratified Ernst & Young LLP as auditor for 2026.

About Sera Prognostics Inc
Market cap
$86M
1Y TSR
−20.2%
3Y TSR
−3.3%
Board grade
C-
Sector
Healthcare
CEO
Zhenya Lindgardt
Last annual meeting: Jun 4, 2026 · View full Sera Prognostics Inc profile →
8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 04, 2026

 

 

Sera Prognostics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40606

26-1911522

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

2749 East Parleys Way

Suite 200

 

Salt Lake City, Utah

 

84109

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (801) 990-0520

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Class A Common Stock, $0.0001 par value per share

 

SERA

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 4, 2026, Sera Prognostics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) via live audio webcast on the Internet. Of the 38,190,966 shares of Class A common stock, par value $0.0001 per share, issued and outstanding and eligible to vote as of the record date of April 13, 2026, a quorum of 25,773,203 shares, or 67.5% of the eligible shares, was present at the meeting or represented by proxy.

At the Annual Meeting, the stockholders: (1) elected each of Kim Kamdar, Ph.D. and Sandra A. J. Lawrence to the Company’s Board of Directors as a Class II director for a term of three years to serve until the 2029 annual meeting of stockholders and until his or her successor is duly elected and qualified or until his or her earlier death, resignation, or removal (“Election of Directors”); and (2) ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (“Auditor Ratification”). A more complete description of each of these matters is set forth in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 24, 2026.

The number of votes cast in favor or against or withheld by the stockholders and, where applicable, the number of abstentions and the number of broker non-votes on each of the foregoing matters are set forth below.

1. Election of Directors

Nominee

 

Shares Voted For

 

 

Shares Voted to Withhold Authority

 

 

Broker Non-votes

 

Kim Kamdar, Ph.D.

 

 

9,749,623

 

 

 

3,062,352

 

 

 

12,961,228

 

Sandra A. J. Lawrence

 

 

12,483,966

 

 

 

328,009

 

 

 

12,961,228

 

2. Auditor Ratification

Shares Voted For

 

Shares Voted Against

 

Shares Abstaining

 

Broker Non-votes

24,917,046

 

856,113

 

44

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

SERA PROGNOSTICS, INC.

 

 

 

 

Date:

June 4, 2026

By:

/s/ Austin Aerts

 

 

 

Austin Aerts
Chief Financial Officer

 


From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Sera Prognostics Inc (SERA)

Reference

Frequently asked questions

When did Sera Prognostics Inc file this 8-K?
Sera Prognostics Inc (SERA) filed this Current Report (Form 8-K) with the SEC on June 4, 2026. The accession number assigned by EDGAR is 0001534969-26-000032.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Stockholders elected two Class II directors to 3-year terms and ratified Ernst & Young LLP as auditor for 2026. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Sera Prognostics Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Sera Prognostics Inc has filed under CIK 1534969, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer